These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 9858314)
1. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2. Emtage PC; Wan Y; Muller W; Graham FL; Gauldie J J Interferon Cytokine Res; 1998 Nov; 18(11):927-37. PubMed ID: 9858314 [TBL] [Abstract][Full Text] [Related]
2. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799 [TBL] [Abstract][Full Text] [Related]
3. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346 [TBL] [Abstract][Full Text] [Related]
4. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Emtage PC; Wan Y; Hitt M; Graham FL; Muller WJ; Zlotnik A; Gauldie J Hum Gene Ther; 1999 Mar; 10(5):697-709. PubMed ID: 10210138 [TBL] [Abstract][Full Text] [Related]
5. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Pützer BM; Hitt M; Muller WJ; Emtage P; Gauldie J; Graham FL Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10889-94. PubMed ID: 9380730 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Pützer BM; Bramson JL; Addison CL; Hitt M; Siegel PM; Muller WJ; Graham FL Hum Gene Ther; 1998 Mar; 9(5):707-18. PubMed ID: 9551618 [TBL] [Abstract][Full Text] [Related]
7. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456 [TBL] [Abstract][Full Text] [Related]
8. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Addison CL; Braciak T; Ralston R; Muller WJ; Gauldie J; Graham FL Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8522-6. PubMed ID: 7667323 [TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574 [TBL] [Abstract][Full Text] [Related]
10. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934 [TBL] [Abstract][Full Text] [Related]
11. Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone. Sun Y; Qian C; Peng D; Prieto J Hum Gene Ther; 2000 Jan; 11(1):127-38. PubMed ID: 10646645 [TBL] [Abstract][Full Text] [Related]
12. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539 [TBL] [Abstract][Full Text] [Related]
13. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533 [TBL] [Abstract][Full Text] [Related]
14. Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. Gaken JA; Hollingsworth SJ; Hirst WJ; Buggins AG; Galea-Lauri J; Peakman M; Kuiper M; Patel P; Towner P; Patel PM; Collins MK; Mufti GJ; Farzaneh F; Darling DC Hum Gene Ther; 1997 Mar; 8(4):477-88. PubMed ID: 9054522 [TBL] [Abstract][Full Text] [Related]
15. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Wendtner CM; Nolte A; Mangold E; Buhmann R; Maass G; Chiorini JA; Winnacker EL; Emmerich B; Kotin RM; Hallek M Gene Ther; 1997 Jul; 4(7):726-35. PubMed ID: 9282174 [TBL] [Abstract][Full Text] [Related]
16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751 [TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Hodge JW; Abrams S; Schlom J; Kantor JA Cancer Res; 1994 Nov; 54(21):5552-5. PubMed ID: 7522961 [TBL] [Abstract][Full Text] [Related]
18. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647 [TBL] [Abstract][Full Text] [Related]